Contingency Management: The Strongest Evidence Nobody Covers

For stimulant use disorder, cocaine, methamphetamine, prescription amphetamines, there are no FDA-approved medications with strong evidence of efficacy. Behavioral treatment is the core. And within behavioral treatment, one approach has the strongest evidence base of any psychosocial intervention for any substance: contingency management (CM).

A SAMHSA 2024 advisory reviewed the research and reported that CM produced methamphetamine use reductions in 26 of 27 randomized controlled trials reviewed, a consistency that is unusual in the behavioral treatment literature.¹ The approach has also been studied for cocaine, opioid, alcohol, and nicotine use disorders, with consistent positive results.

And for most of the last thirty years, almost nobody could access it in the US, because it was essentially not reimbursable.

That has been changing. As of 2025, California, Washington, Montana, Hawaii, and Delaware have approved Medicaid Section 1115 waivers that reimburse CM for Medicaid beneficiaries; several additional states have applications pending. This is a significant policy shift worth understanding.¹²³

What contingency management actually is

Contingency management is, at the mechanical level, simple: provide an immediate, tangible incentive, a small gift card, voucher, prize, or cash, contingent on a verified outcome, usually a negative urine drug test or session attendance. The incentives typically escalate with sustained abstinence and reset with a positive test.

The mechanism is straightforward behavioral science. The reward system in the brain that has been hijacked by the substance responds to other rewards when they are immediate, reliable, and tied to the behavior you want to see more of. CM provides exactly that, in a structured way.

A typical CM protocol for stimulant use disorder:

• Twice-weekly visits for urine drug testing.
• A small incentive for each negative test, escalating with consecutive negatives.
• A bonus incentive at defined milestones (four consecutive negatives, eight consecutive negatives).
• A reset to the baseline incentive when a positive test occurs, without discharging the patient.
• Typical protocol length: 12 to 24 weeks.

The escalating schedule is important. The evidence shows that steep reinforcement, larger rewards for sustained abstinence, outperforms flat reinforcement. The California Medicaid demonstration uses an incentive range of approximately $596 to $1,092 per enrollee over the treatment window.¹

Why it works so well for stimulants

Stimulant use disorder is particularly responsive to CM for a structural reason. The dopamine disruption caused by stimulants blunts the brain's response to ordinary rewards, ordinary social contact, ordinary activities, ordinary accomplishments feel flatter than they did before use started. This is part of why people continue using even when they say they want to stop.

CM introduces a different kind of reward, immediate, tangible, reliable, verified, that can compete with the substance in a way that most therapy-based approaches cannot. It is not asking the patient to value delayed benefits, abstract values, or long-term goals, all of which are specifically disrupted by chronic stimulant use. It is working in the currency the brain is currently responding to.

What the evidence shows

The CM literature is unusually consistent for a behavioral treatment. A few headline findings:

• Stimulant use disorder: 26 of 27 RCTs in a SAMHSA-reviewed sample showed meaningful reductions in methamphetamine use; similar results for cocaine.¹
• Opioid use disorder: CM plus medications for opioid use disorder outperforms MOUD alone on retention and abstinence metrics.
• Alcohol use disorder: Evidence is present but smaller in magnitude than for stimulants.
• Nicotine: CM has a well-established evidence base for smoking cessation.

One caveat that is worth knowing: effects of CM tend to be strongest during the active treatment window and can attenuate after incentives end. The response to this finding, in most clinical implementations, is to extend the intervention duration, combine CM with other evidence-based approaches, and phase incentives down over time rather than abruptly ending them.

Why it has been so hard to access

Insurance coverage for CM in the US has been complicated for three reasons:

1. Incentive value limits. Federal anti-kickback rules and some state insurance regulations limited the size of incentives that could be offered. The literature on what incentive magnitude is required for efficacy has generally concluded that the limits in place were below the threshold for consistent benefit. The Medicaid 1115 waiver program has created a mechanism for states to authorize higher incentive amounts within a structured protocol.²³
2. Provider billing mechanics. CM has not historically had its own CPT code. Providers have had to bill under counseling codes and absorb the cost of incentives, which has meant most clinics could not sustain it.
3. Cultural resistance. A significant contingent in the recovery field has objected to CM on ideological grounds, "paying people to be sober" conflicts with recovery narratives in some traditions. The evidence has nevertheless continued to accumulate.

The California demonstration, the largest to date, has been operating since 2023. Other state programs are rolling out.

Who it fits

CM is particularly useful for:

• Stimulant use disorder, where behavioral treatment is the core and medications have limited efficacy.
• Patients who have not done well in traditional talk-therapy-only outpatient treatment.
• Patients in the early stages of change where the experience of a sustained abstinence window, even a short one, can open up motivation for more.
• Patients receiving medications for opioid use disorder who also have a stimulant use concern.

It is not a standalone approach for most patients. It is typically delivered alongside outpatient therapy, medical care, and other supports.

How to access it

The options depend on where you live:

• In states with approved Medicaid 1115 waivers (California, Washington, Montana, Hawaii, Delaware, and additional states pending): Ask your substance use provider whether they offer CM as a billable service, or search for CM-offering providers through the state Medicaid directory.
• In other states through research programs: Some academic medical centers run CM programs as part of ongoing studies.
• Through specific employer assistance programs and some private insurance: A growing but still limited number of commercial plans are piloting coverage.
• Within the Veterans Health Administration: VA has been an early adopter of CM for stimulant use disorder.

Outside of these pathways, some digital therapeutic products, including the FDA-authorized reSET and reSET-O programs, incorporate CM components as part of their protocols. See the reSET digital therapeutics discussion in the flagship guide.

What CM is not

CM is not:

• A bribery scheme. The incentives are structured to reinforce verified outcomes (negative urine tests, session attendance). The behavioral science underneath is identical to many other contingency-based systems, including school reward programs and workplace incentive structures.
• A replacement for comprehensive treatment. CM is typically one piece of a multi-component plan.
• A long-term substitute for addressing the underlying drivers of use. It is particularly useful at the engagement and early-abstinence stages; other interventions are more useful later.

The bottom line

Contingency management has the strongest evidence base of any psychosocial intervention for stimulant use disorder. It has been difficult to access in the US for structural and cultural reasons, but Medicaid 1115 waivers in a growing list of states are changing that. If stimulant use is part of the picture and you are in a state with CM coverage, asking about it is a reasonable first step. If you are not in one of those states, CM is worth knowing about for when policy catches up.

What to read next

• Ways to Avoid Rehab: The Evidence-Based Guide
• CBT for Substance Use
• Motivational Interviewing

Sources